Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan E Bates

Showing results (121-130 of 293) with videos related to

Pageof 30
Sort By:
Frontiers in Oncology|October 17, 2013
Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapyMarko Jakopovic, Anish Thomas, Sanjeeve Balasubramaniam, et al.
Molecular Cancer Research : MCR|March 2, 2011
Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathwayKenneth K W To, Robert Robey, Zhirong Zhan, et al.
Cancer Metastasis Reviews|February 27, 2007
ABCG2: determining its relevance in clinical drug resistanceRobert W Robey, Orsolya Polgar, John Deeken, et al.
Stem Cells (Dayton, Ohio)|December 23, 2006
Side population analysis using a violet-excited cell-permeable DNA binding dyeWilliam G Telford, Jolene Bradford, William Godfrey, et al.
Journal of Pharmacological and Toxicological Methods|November 30, 2010
Rapid detection of ABC transporter interaction: potential utility in pharmacologyRobert W Robey, Bo Lin, Jean Qiu, et al.
Cancer Management and Research|May 6, 2020
BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future ProspectsWinston Wong, Alexander G Raufi, Rachael A Safyan, et al.
Nature Reviews. Clinical Oncology|December 2, 2024
Getting the right combination to break the epigenetic codeSeda S Tolu, Aaron D Viny, Jennifer E Amengual, et al.
Pharmaceuticals (Basel, Switzerland)|October 8, 2016
Clinical Toxicities of Histone Deacetylase InhibitorsSrividya Subramanian, Susan E Bates, John J Wright, et al.
Molecular Cancer Research : MCR|February 1, 2008
Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cellsKenneth K W To, Orsolya Polgar, Lyn M Huff, et al.
Seminars in Oncology|July 13, 2022
Loss of function STK11 alterations and poor outcomes in non-small-cell lung cancer: Literature and case series of US VeteransHafsa Farooq, Harold Bien, Victor Chang, et al.
Pageof 30

Showing results (121-130 of 293) with videos related to

Sort By:
Pageof 30
Frontiers in Oncology|October 17, 2013
Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapyMarko Jakopovic, Anish Thomas, Sanjeeve Balasubramaniam, et al.
Molecular Cancer Research : MCR|March 2, 2011
Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathwayKenneth K W To, Robert Robey, Zhirong Zhan, et al.
Cancer Metastasis Reviews|February 27, 2007
ABCG2: determining its relevance in clinical drug resistanceRobert W Robey, Orsolya Polgar, John Deeken, et al.
Stem Cells (Dayton, Ohio)|December 23, 2006
Side population analysis using a violet-excited cell-permeable DNA binding dyeWilliam G Telford, Jolene Bradford, William Godfrey, et al.
Journal of Pharmacological and Toxicological Methods|November 30, 2010
Rapid detection of ABC transporter interaction: potential utility in pharmacologyRobert W Robey, Bo Lin, Jean Qiu, et al.
Cancer Management and Research|May 6, 2020
BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future ProspectsWinston Wong, Alexander G Raufi, Rachael A Safyan, et al.
Nature Reviews. Clinical Oncology|December 2, 2024
Getting the right combination to break the epigenetic codeSeda S Tolu, Aaron D Viny, Jennifer E Amengual, et al.
Pharmaceuticals (Basel, Switzerland)|October 8, 2016
Clinical Toxicities of Histone Deacetylase InhibitorsSrividya Subramanian, Susan E Bates, John J Wright, et al.
Molecular Cancer Research : MCR|February 1, 2008
Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cellsKenneth K W To, Orsolya Polgar, Lyn M Huff, et al.
Seminars in Oncology|July 13, 2022
Loss of function STK11 alterations and poor outcomes in non-small-cell lung cancer: Literature and case series of US VeteransHafsa Farooq, Harold Bien, Victor Chang, et al.
Pageof 30